Waters Corp /De/ (WAT) Stock Analysis and Metrics

Waters

NYSE: WAT

$373.14 ▼ -3.29 (-0.87%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap31,055.11 Bn

P/E69,126.88

P/S8,236.16

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)4.86 Bn

Revenue Growth (1y) (Qtr)91.39

Add ratio to table…

About

Waters Corporation is a global leader in analytical instruments and software pioneering innovations in chromatography, mass spectrometry and thermal analysis serving life, materials and food sciences. The company designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC) and mass spectrometry (MS) systems, along with chromatography columns, consumable products and service contracts. It also provides thermal analysis, rheometry and calorimetry instruments through its TA Instruments line and develops software that integrates with its hardware.

Revenue is generated primarily from the sale of analytical instruments including HPLC, UPLC, MS and TA systems. From consumable products such as chromatography columns and reagents. From software offerings that support data acquisition and management. And from service contracts covering maintenance, repair and training.

The company operates through the following segments: Waters and TA.

• Waters: This segment designs, manufactures, sells and services high performance liquid chromatography systems, ultra performance liquid chromatography systems, mass spectrometry instruments, chromatography columns, consumable reagents and associated software, serving customers in pharmaceuticals, biotechnology, clinical diagnostics, environmental testing, food and beverage safety and academic research.

• TA: This segment designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments used to assess material properties such as heat flow, viscosity and stability, serving industries including polymers, pharmaceuticals, batteries, electronics and materials research.

Waters Corporation holds a leading position in the analytical instrumentation market competing with Agilent Technologies, Shimadzu Corporation, Bruker Corporation, Danaher Corporation and Thermo Fisher Scientific Inc. in chromatography and mass spectrometry. In thermal analysis the company faces competition from PerkinElmer, NETZSCH Geraetebau GmbH, Malvern PANalytical Ltd., Spectris plc and Anton Paar GmbH. The company differentiates itself through product performance, reliability, innovative technology and a strong service network.

The company serves a diverse customer base that includes pharmaceutical companies, biotechnology firms, contract research organizations, clinical laboratories, food and beverage producers, environmental testing labs, academic institutions and government agencies such as the United States Food and Drug Administration and the Environmental Protection Agency.

Investment Thesis

▲ Bull case

Waters Corporation is positioned to capitalize on a structural inflection point in China's pharmaceutical industry, where the company's strategic localization of manufacturing and product portfolios—building on the successful playbook from its Analytical Sciences division—will unlock significant growth in Biosciences and Diagnostics. CEO Udit Batra's assertion that China is now the global biotech leader, with roughly one-third of molecules in-licensed by large pharma originating from China, reveals a secular shift beyond temporary market fluctuations. The integration of Waters' high-resolution mass spectrometry and flow cytometry platforms with China's rapidly expanding contract development and manufacturing organization (CDMO) ecosystem and innovative biotech sector creates a self-reinforcing cycle: as Chinese innovators scale from discovery to full drug development, they require Waters' full suite of analytical tools across bioseparations, detection, and informatics. This dynamic is already bearing fruit, with pharma growth in China exceeding 50% in Q1, and the company's localized manufacturing initiative in Suzhou—set to begin yielding orders in Q3—addresses export restrictions and localization gaps that previously constrained Flow research reagent availability. Unlike competitors relying on legacy export models, Waters is embedding itself into China's innovation value chain, turning a perceived headwind into a sustainable growth engine that will drive mid- to high-single-digit organic expansion in its acquired businesses through 2026 and beyond, independent of cyclical flu season or DRG-related headwinds.
The company's revenue synergy realization is significantly ahead of schedule and underappreciated by the market, with early wins in instrument replacement, service plan attachment, and e-commerce creating a compounding effect that will accelerate adjusted EPS growth beyond the guided 10% to 11% range for FY26. Management explicitly noted that the $35 million revenue synergy guidance for acquired businesses excludes pricing discipline benefits, reagent rental contract compliance opportunities, and tariff mitigation—areas where Waters is already seeing tangible results. For instance, the review of 1,600 U.S. Diagnostic Solutions reagent rental contracts revealed approximately 700 out of compliance, representing a double-digit million annual shortfall. Similarly, the accelerated launch of BACTEC FXI by 3 to 5 months due to Waters' execution discipline is capturing revenue from an installed base where over 50% of the 22,000 units ripe for replacement are over five years old and over 25% are over ten years old. These near-term levers, combined with the 180-day plan's doubling of weekly call rates in U.S. Advanced Diagnostics and the establishment of new deal desks, are creating a visibility and conversion uplift that is not yet reflected in guidance. As these initiatives scale through Q3 and Q4, they will drive incremental revenue and margin expansion that compounds with organic growth, positioning Waters to exceed its own conservative full-year outlook and deliver adjusted EPS growth in the low-teens range through synergistic acceleration rather than mere organic expansion.
Waters' innovation pipeline in high-growth adjacencies—particularly in structural and spatial omics and next-generation microbiology—is creating defensible, long-term differentiation that will sustain premium pricing and market share gains in regulated, high-volume testing environments. The launch of the Cyclic IMS P20 Mass Spectrometer, with its >10-fold increase in MS/MS sensitivity and over 50% extended mass range to over 100 kDa, directly addresses the rising demand for deeper biological insight in complex therapeutic targets like those in Type II diabetes and neurodegeneration, where low-abundance species are critical to mechanism elucidation. Simultaneously, the Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity and twice the acquisition speed of its predecessor, enabling high-throughput multiomics research at scale. These platforms are not incremental upgrades but paradigm-shifting tools that lock in customer retention through superior data quality and workflow efficiency, especially in biopharma and academic labs pursuing biomarker discovery and therapeutic target validation. Coupled with the FDA-cleared BD BACTEC FXI Culture System—which reduces time to detection by three hours and offers automated gravimetric volume confirmation—Waters is building an end-to-end solution stack from sample prep to detection to analytics that addresses unmet needs in sepsis diagnostics and cancer screening. This integrated innovation engine, supported by the company's historical R&D allocation of 70-80% to bioseparations, ensures that Waters remains a growth leader not just through cyclical demand but through technological leadership that commands pricing power and drives service attachment rates well into the next decade.

Waters Corporation is positioned to capitalize on a structural inflection point in China's pharmaceutical industry, where the company's strategic localization of manufacturing and product portfolios—building on the successful playbook from its Analytical Sciences division—will unlock significant growth in Biosciences and Diagnostics. CEO Udit Batra's assertion that China is now the global biotech leader, with roughly one-third of molecules in-licensed by large pharma originating from China, reveals a secular shift beyond temporary market fluctuations. The integration of Waters' high-resolution mass spectrometry and flow cytometry platforms with China's rapidly expanding contract development and manufacturing organization (CDMO) ecosystem and innovative biotech sector creates a self-reinforcing cycle: as Chinese innovators scale from discovery to full drug development, they require Waters' full suite of analytical tools across bioseparations, detection, and informatics. This dynamic is already bearing fruit, with pharma growth in China exceeding 50% in Q1, and the company's localized manufacturing initiative in Suzhou—set to begin yielding orders in Q3—addresses export restrictions and localization gaps that previously constrained Flow research reagent availability. Unlike competitors relying on legacy export models, Waters is embedding itself into China's innovation value chain, turning a perceived headwind into a sustainable growth engine that will drive mid- to high-single-digit organic expansion in its acquired businesses through 2026 and beyond, independent of cyclical flu season or DRG-related headwinds.
The company's revenue synergy realization is significantly ahead of schedule and underappreciated by the market, with early wins in instrument replacement, service plan attachment, and e-commerce creating a compounding effect that will accelerate adjusted EPS growth beyond the guided 10% to 11% range for FY26. Management explicitly noted that the $35 million revenue synergy guidance for acquired businesses excludes pricing discipline benefits, reagent rental contract compliance opportunities, and tariff mitigation—areas where Waters is already seeing tangible results. For instance, the review of 1,600 U.S. Diagnostic Solutions reagent rental contracts revealed approximately 700 out of compliance, representing a double-digit million annual shortfall. Similarly, the accelerated launch of BACTEC FXI by 3 to 5 months due to Waters' execution discipline is capturing revenue from an installed base where over 50% of the 22,000 units ripe for replacement are over five years old and over 25% are over ten years old. These near-term levers, combined with the 180-day plan's doubling of weekly call rates in U.S. Advanced Diagnostics and the establishment of new deal desks, are creating a visibility and conversion uplift that is not yet reflected in guidance. As these initiatives scale through Q3 and Q4, they will drive incremental revenue and margin expansion that compounds with organic growth, positioning Waters to exceed its own conservative full-year outlook and deliver adjusted EPS growth in the low-teens range through synergistic acceleration rather than mere organic expansion.
Waters' innovation pipeline in high-growth adjacencies—particularly in structural and spatial omics and next-generation microbiology—is creating defensible, long-term differentiation that will sustain premium pricing and market share gains in regulated, high-volume testing environments. The launch of the Cyclic IMS P20 Mass Spectrometer, with its >10-fold increase in MS/MS sensitivity and over 50% extended mass range to over 100 kDa, directly addresses the rising demand for deeper biological insight in complex therapeutic targets like those in Type II diabetes and neurodegeneration, where low-abundance species are critical to mechanism elucidation. Simultaneously, the Xevo MRT P10 MS delivers up to 20x higher MS/MS sensitivity and twice the acquisition speed of its predecessor, enabling high-throughput multiomics research at scale. These platforms are not incremental upgrades but paradigm-shifting tools that lock in customer retention through superior data quality and workflow efficiency, especially in biopharma and academic labs pursuing biomarker discovery and therapeutic target validation. Coupled with the FDA-cleared BD BACTEC FXI Culture System—which reduces time to detection by three hours and offers automated gravimetric volume confirmation—Waters is building an end-to-end solution stack from sample prep to detection to analytics that addresses unmet needs in sepsis diagnostics and cancer screening. This integrated innovation engine, supported by the company's historical R&D allocation of 70-80% to bioseparations, ensures that Waters remains a growth leader not just through cyclical demand but through technological leadership that commands pricing power and drives service attachment rates well into the next decade.

▼ Bear case

Waters Corporation faces significant integration execution risk in its acquired Biosciences and Diagnostic Solutions businesses, where early performance gains may be temporary and overstated due to low-baseline comparisons and one-time operational improvements rather than sustainable market-driven growth. While Q1 results showed flat pro forma revenue growth for the acquired businesses (up 1% for Diagnostic Solutions and down 1% for Biosciences), management attributed this to a $20 million respiratory testing headwind and cited ex-China growth of 4% and 6% respectively as evidence of underlying strength. However, this ex-China growth is heavily influenced by the 180-day plan's commercial execution initiatives—such as doubled call rates, pricing discipline, and reagent rental contract compliance—which are near-term, resource-intensive actions that may not be scalable or maintainable at the same pace through the rest of 2026. The company's reliance on these operational levers to drive growth masks a fundamental weakness: the underlying demand in core Flow research and Flow clinical remains pressured by U.S. academic and government trends and ongoing China-related constraints, including export restrictions on high-parameter products and lack of localized product portfolios. Until manufacturing localization in China (slated for Q3) and product portfolio adaptation are fully realized, the Biosciences division remains vulnerable to secular shifts in research funding and geopolitical trade barriers, making the current growth inflection potentially fragile and dependent on continued management intervention rather than organic market recovery.
The company's margin expansion trajectory is at risk from rising operating expenses and integration-related costs that are not fully captured in current guidance, particularly as the benefits of cost synergies are delayed and offset by incremental investments in commercial capacity and digital infrastructure. Although Waters raised its FY26 adjusted EBIT margin guidance to 28.2%, this assumes timely realization of $55 million in cost synergies from organizational optimization and procurement savings, which are only expected to hit the P&L beginning in Q3. In the interim, the company is incurring significant expenses: Q1 GAAP operating loss of $47 million (vs. $151 million income in Q1 FY25) was driven by $152 million in purchased intangibles amortization and $99 million in inventory step-up, with acquisition-related costs alone totaling $83 million. Furthermore, Waters is scaling its e-commerce team to over 100 FTEs in Bangalore and increasing sales field activity through higher call volumes and customer visits—costs that are being absorbed before synergies flow through. While management frames these as investments, they represent a near-term drag on profitability that could delay margin expansion if synergy realization lags or if revenue growth in the acquired businesses fails to meet expectations. The guidance assumes a prudent 6% organic constant currency growth in the second half of the year for legacy Waters and 1.5 percentage points above Q2 guidance for acquired businesses, but this leaves little room for error if macroeconomic headwinds—such as prolonged Middle East conflict affecting freight and raw material costs—intensify or if customer adoption of new platforms like BACTEC FXI is slower than anticipated due to budget constraints in clinical labs.
Waters' growth outlook is overly dependent on the continued strength of idiosyncratic drivers in its legacy Analytical Sciences business, which may not be as durable or scalable as management suggests, particularly as the company laps against exceptionally strong prior-year comparisons and faces increasing competition in high-growth segments like PFAS testing and GLP-1 analysis. While Q1 pharma growth was mid-teens and Asia grew nearly 30% (led by over 50% in China), this performance was bolstered by pull-forward demand in chemistry (e.g., MaxPeak Premier columns) and instrument replacement cycles that are inherently cyclical. The company's own CFO acknowledged that the 13% constant currency growth in chemistry is being guided at only 6.5% for the full year due to baseline strength and prudence, indicating expectations of mean reversion. Similarly, the instrument replacement cycle—while supported by aging installed bases (e.g., over 50% of BACTEC units over five years old)—is not a permanent growth engine, as replacement activity will eventually taper once the backlog is cleared. Moreover, the company's reliance on niche drivers like India generics and Chinese biotech exposes it to policy volatility: any shift in China's innovation incentives, India's generic drug pricing regulations, or U.S. Inflation Reduction Act implementation could abruptly alter demand. Without a clear, diversified growth engine beyond these cyclical and policy-sensitive themes, Waters risks reverting to its historical mid-single-digit organic growth rate once the current momentum from new product launches and integration efforts fades, leaving the combined entity vulnerable to multiple compression if EPS growth fails to exceed the low-teens range sustainably.

Waters Corporation faces significant integration execution risk in its acquired Biosciences and Diagnostic Solutions businesses, where early performance gains may be temporary and overstated due to low-baseline comparisons and one-time operational improvements rather than sustainable market-driven growth. While Q1 results showed flat pro forma revenue growth for the acquired businesses (up 1% for Diagnostic Solutions and down 1% for Biosciences), management attributed this to a $20 million respiratory testing headwind and cited ex-China growth of 4% and 6% respectively as evidence of underlying strength. However, this ex-China growth is heavily influenced by the 180-day plan's commercial execution initiatives—such as doubled call rates, pricing discipline, and reagent rental contract compliance—which are near-term, resource-intensive actions that may not be scalable or maintainable at the same pace through the rest of 2026. The company's reliance on these operational levers to drive growth masks a fundamental weakness: the underlying demand in core Flow research and Flow clinical remains pressured by U.S. academic and government trends and ongoing China-related constraints, including export restrictions on high-parameter products and lack of localized product portfolios. Until manufacturing localization in China (slated for Q3) and product portfolio adaptation are fully realized, the Biosciences division remains vulnerable to secular shifts in research funding and geopolitical trade barriers, making the current growth inflection potentially fragile and dependent on continued management intervention rather than organic market recovery.
The company's margin expansion trajectory is at risk from rising operating expenses and integration-related costs that are not fully captured in current guidance, particularly as the benefits of cost synergies are delayed and offset by incremental investments in commercial capacity and digital infrastructure. Although Waters raised its FY26 adjusted EBIT margin guidance to 28.2%, this assumes timely realization of $55 million in cost synergies from organizational optimization and procurement savings, which are only expected to hit the P&L beginning in Q3. In the interim, the company is incurring significant expenses: Q1 GAAP operating loss of $47 million (vs. $151 million income in Q1 FY25) was driven by $152 million in purchased intangibles amortization and $99 million in inventory step-up, with acquisition-related costs alone totaling $83 million. Furthermore, Waters is scaling its e-commerce team to over 100 FTEs in Bangalore and increasing sales field activity through higher call volumes and customer visits—costs that are being absorbed before synergies flow through. While management frames these as investments, they represent a near-term drag on profitability that could delay margin expansion if synergy realization lags or if revenue growth in the acquired businesses fails to meet expectations. The guidance assumes a prudent 6% organic constant currency growth in the second half of the year for legacy Waters and 1.5 percentage points above Q2 guidance for acquired businesses, but this leaves little room for error if macroeconomic headwinds—such as prolonged Middle East conflict affecting freight and raw material costs—intensify or if customer adoption of new platforms like BACTEC FXI is slower than anticipated due to budget constraints in clinical labs.
Waters' growth outlook is overly dependent on the continued strength of idiosyncratic drivers in its legacy Analytical Sciences business, which may not be as durable or scalable as management suggests, particularly as the company laps against exceptionally strong prior-year comparisons and faces increasing competition in high-growth segments like PFAS testing and GLP-1 analysis. While Q1 pharma growth was mid-teens and Asia grew nearly 30% (led by over 50% in China), this performance was bolstered by pull-forward demand in chemistry (e.g., MaxPeak Premier columns) and instrument replacement cycles that are inherently cyclical. The company's own CFO acknowledged that the 13% constant currency growth in chemistry is being guided at only 6.5% for the full year due to baseline strength and prudence, indicating expectations of mean reversion. Similarly, the instrument replacement cycle—while supported by aging installed bases (e.g., over 50% of BACTEC units over five years old)—is not a permanent growth engine, as replacement activity will eventually taper once the backlog is cleared. Moreover, the company's reliance on niche drivers like India generics and Chinese biotech exposes it to policy volatility: any shift in China's innovation incentives, India's generic drug pricing regulations, or U.S. Inflation Reduction Act implementation could abruptly alter demand. Without a clear, diversified growth engine beyond these cyclical and policy-sensitive themes, Waters risks reverting to its historical mid-single-digit organic growth rate once the current momentum from new product launches and integration efforts fades, leaving the combined entity vulnerable to multiple compression if EPS growth fails to exceed the low-teens range sustainably.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password